If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - [Immunodiacnostic Systems]

11 Jun 2021 14:40

RNS Number : 6864B
Axxion S.A.
11 June 2021
 

FORM 8.3

Amendment - this form replaces RNS number 3021Z, changes made to section 1

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Frankfurter - Value Focus Fund (*)

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Immunodiagnostic Systems Holdings PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

17th May 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

(*) Baader Bank AG is acting as delegated portfolio manager on behalf of Frankfurter - Value Focus Fund

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

5p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,439,648

8.48

 

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

2,439,648

8.48

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price p

er unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

 

NO

 

 

Date of disclosure:

 

20th May 2021

Contact name:

Stephan Demuth

Telephone number:

(+352)769494570

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETGPURWQUPGGWG
Date   Source Headline
29th Oct 20077:00 amRNSNotice of Results
5th Oct 200712:11 pmRNSNotifiable Interest
2nd Oct 20077:01 amRNSSenior Management Appointment
17th Sep 20073:33 pmRNSNotifiable Interest
17th Sep 20077:01 amRNSBoard Appointment
10th Sep 20073:48 pmRNSNotifiable Interest
3rd Sep 20077:01 amRNSTotal Voting Rights
3rd Sep 20077:00 amRNSCompletion of Acquisition
31st Aug 20073:16 pmRNSAGM Statement
28th Aug 20071:48 pmRNSResult of EGM
20th Aug 200712:36 pmRNSNotifiable Interest
20th Aug 20079:53 amRNSAIM Rule 26
3rd Aug 20077:00 amRNSProposed Acquisition
31st Jul 200711:03 amRNSTotal Voting Rights
26th Jul 20077:01 amRNSCompletion of acquisition
16th Jul 20075:57 pmRNSCorrection re. dividend dates
16th Jul 20077:01 amRNSFinal Results
29th Jun 20077:01 amRNSNotice of Results
18th Jun 20077:02 amRNSImmunoassay kits agreement
8th May 20077:01 amRNSNotifiable Interest
3rd May 20073:39 pmRNSDirectors Dealing
21st Mar 20077:00 amRNSTrading Statement
20th Mar 20075:33 pmRNSNotifiable Interest
13th Mar 20077:00 amRNSBoard Appointment
12th Feb 20077:02 amRNSBoard Appointment
31st Jan 20077:02 amRNSProduct launch
4th Jan 20077:00 amRNSProduct Launch
21st Dec 200612:48 pmRNSTotal Voting Rights
5th Dec 20069:44 amRNSDirector/PDMR Shareholding
4th Dec 20067:02 amRNSAutomation agreement
15th Nov 20068:54 amRNSHolding(s) in Company
6th Nov 20067:01 amRNSInterim Results
19th Oct 200611:34 amRNSNotice of Results
10th Oct 20067:02 amRNSIDS launches into Austria
13th Sep 20067:00 amRNSLaunch of new assay kit
22nd Aug 200611:04 amRNSAGM Statement
17th Jul 20064:35 pmRNSHolding(s) in Company
5th Jul 20067:00 amRNSFinal Results
30th May 20067:03 amRNSMarketing & sales agreement
15th May 20067:01 amRNSDirectorate Change
12th Apr 20067:01 amRNSDirector/PDMR Shareholding
30th Mar 20067:01 amRNSPre-close Trading update
21st Feb 20062:38 pmRNSDirectors Dealing
7th Nov 20057:00 amRNSInterim Results
26th Oct 20059:52 amRNSNotice of Results
26th Sep 20057:01 amRNSBoard Appointment
6th Sep 200511:18 amRNSAGM Statement
12th Aug 200510:42 amRNSFDA Approval
12th Jul 20057:01 amRNSFinal Results
6th Jul 20053:19 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.